Gain Therapeutics (NASDAQ:GANX) Receives “Buy” Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $6.00 price target on the stock.

A number of other research firms have also issued reports on GANX. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a report on Monday, March 17th. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Scotiabank assumed coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price for the company. Finally, Roth Mkm reiterated a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Trading Down 8.7 %

Shares of Gain Therapeutics stock opened at $1.89 on Friday. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The business has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.07. The company has a market capitalization of $50.13 million, a P/E ratio of -1.72 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. Sell-side analysts anticipate that Gain Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at $198,000. Geode Capital Management LLC raised its position in shares of Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the period. Jones Financial Companies Lllp boosted its holdings in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after acquiring an additional 44,750 shares during the last quarter. Northern Trust Corp boosted its holdings in Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics during the fourth quarter valued at about $65,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.